Medimmune is welcoming biotech firm Amplimmune to the AstraZeneca family in a deal that could be worth up to $500m for the Johns Hopkins University spin-out. Medimmune, the research and development unit of life sciences conglomerate AstraZeneca, acquired 100% of Amplimmune’s shares for an initial consideration of $225m. A further $275m is available based on…
Medimmune’s $500m for Amplimmune
Aug 27, 2013 •
LEADERSHIP SOCIETYInforming, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.
More featured content
Resistance is futile: seven superconductor companies that want to change the world
From healthcare to fusion to quantum computing to space, superconductors have the potential to revolutionise the world. And the technology is finally ready to commercialise.
UK universities urged to lower spinout stakes
A new report recommends stakes of less than 25% but fails to address the issue of access to early-stage capital.
Feb 7, 2024
Mar 14, 2024
Monterey, CA (USA)
Jun 26, 2024